Search research articles
Contact Us
Filters
Showing results (51-60 of 75) with videos related to
Page
of 8
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 14, 2019
Biodistribution and Dosimetry of Intraventricularly Administered <sup>124</sup>I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors
Neeta Pandit-Taskar, Pat B Zanzonico, Kim Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2020
Safety and Feasibility of PARP1/2 Imaging with <sup>18</sup>F-PARPi in Patients with Head and Neck Cancer
Heiko Schöder, Paula Demétrio De Souza França, Reiko Nakajima, et al.
Cancer Research
|
May 18, 2018
Metabolic Imaging of the Human Brain with Hyperpolarized <sup>13</sup>C Pyruvate Demonstrates <sup>13</sup>C Lactate Production in Brain Tumor Patients
Vesselin Z Miloushev, Kristin L Granlund, Rostislav Boltyanskiy, et al.
Neuro-Oncology
|
February 19, 2025
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG)
Mark M Souweidane, Evan D Bander, Pat Zanzonico, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
Randy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
The Lancet. Oncology
|
May 31, 2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics
Andrew M Scott, Brian M Zeglis, Suzanne E Lapi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 21, 2024
<sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer
Samuel L Cytryn, Neeta Pandit-Taskar, Melissa A Lumish, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Cell Metabolism
|
October 1, 2019
Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1
Kristin L Granlund, Sui-Seng Tee, Hebert A Vargas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 13, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A O'Donoghue, Shutian Ruan, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 75) with videos related to
Sort By:
Page
of 8
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 14, 2019
Biodistribution and Dosimetry of Intraventricularly Administered <sup>124</sup>I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors
Neeta Pandit-Taskar, Pat B Zanzonico, Kim Kramer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 5, 2020
Safety and Feasibility of PARP1/2 Imaging with <sup>18</sup>F-PARPi in Patients with Head and Neck Cancer
Heiko Schöder, Paula Demétrio De Souza França, Reiko Nakajima, et al.
Cancer Research
|
May 18, 2018
Metabolic Imaging of the Human Brain with Hyperpolarized <sup>13</sup>C Pyruvate Demonstrates <sup>13</sup>C Lactate Production in Brain Tumor Patients
Vesselin Z Miloushev, Kristin L Granlund, Rostislav Boltyanskiy, et al.
Neuro-Oncology
|
February 19, 2025
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG)
Mark M Souweidane, Evan D Bander, Pat Zanzonico, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled <sup>89</sup>Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer
Randy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.
The Lancet. Oncology
|
May 31, 2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics
Andrew M Scott, Brian M Zeglis, Suzanne E Lapi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 21, 2024
<sup>18</sup>F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer
Samuel L Cytryn, Neeta Pandit-Taskar, Melissa A Lumish, et al.
Medrxiv : the Preprint Server for Health Sciences
|
January 23, 2024
First-in-human imaging with [<sup>89</sup>Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumors of the lung and prostate
Salomon Tendler, Mark P Dunphy, Matthew Agee, et al.
Cell Metabolism
|
October 1, 2019
Hyperpolarized MRI of Human Prostate Cancer Reveals Increased Lactate with Tumor Grade Driven by Monocarboxylate Transporter 1
Kristin L Granlund, Sui-Seng Tee, Hebert A Vargas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 13, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake
Neeta Pandit-Taskar, Joseph A O'Donoghue, Shutian Ruan, et al.
Page
of 8